Cannabinoid receptors and their ligands.

By R. Pertwee, R. Ross. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2002

595 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/5bc527eaae75e391275ce4dd31619589c6aa1c83

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. R. Pertwee
2. V. Di Marzo
3. K. Mackie
4. R. Ross
5. George Kunos
6. R. Mechoulam
7. Allyn C. Howlett
8. Stephen P. H. Alexander

In Pharmacology

1. R. Pertwee
2. V. Di Marzo
3. K. Mackie
4. George Kunos
5. R. Ross
6. R. Mechoulam
7. Allyn C. Howlett
8. P. Greasley

Citations in the corpus

• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors (2002, background): “…of SAR data for anandamide is complicated by evidence firstly, that this fatty acid amide is also an agonist for non-CB 1 , non-CB 2 receptors, and secondly, that some of its metabolites also have pharmacological activity (Adams et al., 1998; Craib et al., 2001; Pertwee and Ross, 2002).”
• International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (2010, background): “CB1 receptors are found mainly at the terminals of central and peripheral neurons, where they usually mediate inhibition of ongoing release of a number of different excitatory and inhibitory neurotransmitters (for review, see Howlett et al., 2002; Pertwee and Ross, 2002; Szabo and Schlicker, 2005).”
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin (2008, background): “…CB1 receptors to inhibit the release of glutamate onto GABAergic neurons that project from the nucleus accumbens to the ventral tegmental area where they exert an inhibitory effect on the firing of dopaminergic neurons projecting back to the nucleus accumbens (reviewed in Pertwee and Ross, 2002).”
• Anandamide and vanilloid TRPV1 receptors (2003, background): “Anandamide (Narachidonoyl-ethanolamide) is an ‘endocannabinoid’, as defined by its ability to bind to and activate cannabinoid CB1 and CB2 receptors (see Pertwee & Ross, 2002); however, the pharmacology of this compound is complex (see Di Marzo, 2002; Di Marzo et al., 2002b).”